Doubled Position in Pfizer
The PFE drop has provided a nice opportunity. My only hope is that the market as a whole doesn't collapse. Based on a valuation range of $28-35, using current numbers, $21.25 is just too good to pass up for a company with a long history of generating positive free cash flow.
In this case, I see no reason to hedge, although I will sell covered calls, limiting the upside but reducing the portfolio risk.
In this case, I see no reason to hedge, although I will sell covered calls, limiting the upside but reducing the portfolio risk.
<< Home